Short, Targeted Radiation Therapy a Good Option for Early Stage Breast Cancer, Phase 3 Trial Shows

Short, Targeted Radiation Therapy a Good Option for Early Stage Breast Cancer, Phase 3 Trial Shows
The quality of life of women treated with a targeted form of radiation therapy, called accelerated partial breast irradiation (APBI), is similar to those who get the standard whole-breast radiation therapy, results from a Phase 3 trial show. This makes it a good option for women with early breast cancer after they undergo breast-conserving surgery since APBI treatment takes less than a week, instead of the three to six weeks required for the traditional radiotherapy. The study, “Quality-of-life results for accelerated partial breast irradiation with interstitial brachytherapy versus whole-breast irradiation in early breast cancer after breast-conserving surgery (GEC-ESTRO): 5-year results of a randomised, phase 3 trial,” was published in the journal The Lancet Oncology. APBI uses small tubes to deliver a high dose of radiation directly into the tumor site over a short period of time. "This treatment focuses only on the area of the breast where the tumor has been removed and so it offers a number of advantages. It allows us to deliver a higher dose of radiation to a smaller area, which means the course of treatment is shortened from three to six weeks down to one week or less. It also makes it easier to avoid unnecessary radiation to other parts of the body, such as the heart and lungs,” Rebekka Schäfer, MD, a clinician in the department of radiation oncology at University Hospital
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.